Ionis and Novartis expand Lp(a) collaboration; Ionis gets $60M upfront for next-gen therapy

IONIS PHARMACEUTICALS INC

Ionis receives $60 million upfront from Novartis for next-generation Lp(a) compound.
Builds on existing pelacarsen collaboration; Novartis to handle development and commercialization.
Agreement subject to HSR antitrust clearance.
Ionis eligible for additional milestone payments and tiered royalties.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IONIS PHARMACEUTICALS INC entered into Agreement with Novartis Pharma AG (effective 2023-08-03).

Action: entry
Agreement: collaboration
Counterparty: Novartis Pharma AG
Effective: 2023-08-03

Exact text from the filing

On August 3, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing that the Company entered into a collaboration and license agreement (the “ Agreement ”) with Novartis Pharma AG (“ Novartis ”) to discover, develop and commercialize a novel medicine for patients with lipoprotein(a)-driven cardiovascular disease.

View on SEC.gov

302 material agreements filed in the last 30 days. Browse all material agreements →

IONIS PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001140361-23-037887

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.